PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaBusiness Wire • 11/29/23
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaBusiness Wire • 11/29/23
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in SchizophreniaBusiness Wire • 11/17/23
Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in SchizophreniaBusiness Wire • 11/16/23
Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond DopamineSeeking Alpha • 11/06/23
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesBusiness Wire • 11/02/23
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute CongressBusiness Wire • 11/01/23
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023Business Wire • 10/19/23
Karuna Therapeutics: KarXT Could Become A New Standard Of Care In SchizophreniaSeeking Alpha • 10/16/23
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) CongressBusiness Wire • 10/04/23
Karuna Takes A Big Step In Schizophrenia Treatment. Shares Jump Higher.Investors Business Daily • 09/28/23
Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of SchizophreniaBusiness Wire • 09/28/23
Karuna Therapeutics, Inc. (KRTX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/03/23
Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business UpdatesBusiness Wire • 08/03/23